corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published in 2005

There are 1256 items in the Healthy Skepticism Library that were published in 2005.

Page 13 of 13 pages ‹ First  < 11 12 13

HSL4929
Lemmens T.
Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada.
Health Law Rev 2005; 13:(2-3):39-50

HSL4944
Regnstrom K, Burgess DJ.
Pharmacogenomics and its potential impact on drug and formulation development.
Crit Rev Ther Drug Carrier Syst 2005; 22:(5):465-92
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4847&uid=16313234&db=PubMed&url=http://www.begellhouse.com/journals/3667c4ae6e8fd136,0f80ebac03395679,22c907bb0f290242.html

HSL4988
Mastai R.
[Clinical practice and pharmaceutical industry: an always difficult relationship].
Acta Gastroenterol Latinoam 2005; 35:(4):209-10

HSL4992
Lau Y.
Is banning direct to consumer advertising of prescription medicine justified paternalism?
J Bioeth Inq 2005; 2:(2):69-74

HSL4993
Jordens C, Anderson L.
Should we be concerned about direct-to-consumer advertising of prescription drugs?
J Bioeth Inq 2005; 2:(2):61-2

HSL5098
Fernandez R, Gao C, Genkin W, Ghandi T, Graham R, Hou J, Hsu E, Hwang J.
Changing perspectives on dental advertising.
J Am Coll Dent 2005 Fall; 72:(3):24-6

HSL5099
Adamjee A, Alfi D, Agarwal D, Braithwaite Y, Chan J, Chey M, Cho H, Choi C.
What does the fact of advertising convey to patients?
J Am Coll Dent 2005 Fall; 72:(3):22-3

HSL5212
Cohen JG.
Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game
J Law Med Ethics 2005 Wint 00; 33:(4):866-9

HSL5238
Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K, Gaebel K.
Can current electronic systems meet drug safety and effectiveness requirements?
AMIA Annu Symp Proc 2005; 335-9

HSL5372
Regnier K, Kopelow M, Lane D, Alden E.
Accreditation for learning and change: quality and improvement as the outcome.
J Contin Educ Health Prof 2005 Sum; 25:(3):174-82
http://www3.interscience.wiley.com/cgi-bin/abstract/112093715/ABSTRACT?CRETRY=1&SRETRY=0

HSL5421
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005; 28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/

HSL5439
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005; 22:(4):73-107

HSL5440
Macias W, Stavchansky Lewis L.
How well do direct-to-consumer, DTC, prescription drug web sites meet FDA guidelines and public policy concerns?
Health Mark Q 2005; 22:(4):45-71

HSL5441
Parker RS, Pettijohn CE.
Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians.
Health Mark Q 2005; 22:(4):27-43

HSL19040
Woloshin S, Schwartz LM, Welch HG
Patients and medical statistics. Interest, confidence, and ability.
J Gen Intern Med 2005; 20:(11):996-1000
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490265/?tool=pubmed

HSL5579
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005; 183:(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html

HSL5740
Curry TJ, Jarosch J, Pacholok , S.
Are Direct to Consumer Advertisements of Prescription Drugs Educational?: Comparing 1992 to 2002.
Journal of Drug Education 2005; 35:(3):217-232

HSL5753
Miller D .
Commentary: Psychologically Naive Assumptions about the Perils of Conflicts of Interest
Moore , D A, Cain , Dm , Loewenstein G. Conflicts of interest: Challenges and solutions in business, law, medicine, and public policy. New York, NY: Cambridge University Press 2005

HSL5784
Seamon MJ, Clauson KA.
Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
J Herb Pharmacother 2005; 5:(3):67-86

HSL5842
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005; 28:(6):495-512

HSL7411
Gilad J, Moran L, Schlaeffer F, Borer A.
Antibiotic drug advertising in medical journals.
Scand J Infect Dis 2005; 37:(11-12):910-2
http://www.ncbi.nlm.nih.gov/pubmed/16308229

HSL8777
Singh AR, Singh SA.
The connection between academia and industry
Mens Sana Monographs 2005; 3:(1):5-35
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=5;epage=35;aulast=Singh

HSL8778
Singh AR, Singh SA.
Public welfare agenda or corporate research agenda?
Mens Sana Monographs 2005; 3:(1):41-80
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=41;epage=80;aulast=Singh

HSL8824
Kassirer JP.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
New York: Oxford University Press, USA 2005
http://www.oup.com/us/catalog/general/subject/Economics/Health/?view=usa&ci=9780195300048

HSL8825
Abramson J.
Overdosed America: The Broken Promise of American Medicine
New York: Harper Collins 2005
http://www.harpercollins.com/books/9780060568535/Overdosed_America/index.aspx

HSL8826
Moynihan R, Cassels A.
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients
New York: Nation Books 2005
http://web.archive.org/web/20070416141611/http://www.nationbooks.org/book.mhtml?t=sickness

HSL8994
Moore DA, Cain DM, Loewenstein G, Bazerman MH.
Conflicts of Interest: Challenges and Solutions in Business, Law, Medicine, and Public Policy
New York: Cambridge University Press 2005
http://www.cambridge.org/catalogue/catalogue.asp?isbn=9780511128370&ss=fro

HSL19377
Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis
OHRI 2005
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

HSL9987
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005; 35:(2):237 - 256
http://baywood.metapress.com/(iurdbb45zrns2y55w4i3yn45)/app/home/contribution.asp?referrer=parent&backto=issue,2,13;journal,9,146;linkingpublicationresults,1:300313,1

HSL9988
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win; 12:(1):e22-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16055941&query_hl=8&itool=pubmed_DocSum

HSL10299
Narhi U, Vanakoski J, Sihvo S.
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
Clin Drug Investig 2005; 25:(4):243-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17523774

HSL12608
Harp TN, McKenna M, Shute N.
Media, law, and the public's health.
J Law Med Ethics 2005 Win; 33:(4):
http://www.ncbi.nlm.nih.gov/pubmed/16689163?dopt=Abstract

HSL13288
Kotabe M, Peloso A, Gregory GD, Noble G, MacArthur W, Neal C, Riege A.
International Marketing: An Asia Pacific Focus
Milton, Qld: John Wiley and Sons Australia, Ltd. 2005
http://web.archive.org/web/20060824005525/http://www.johnwiley.com.au/highered/im/index.htm

HSL16340
Grosjean O
La santé à quel prix? Bruxelles: Couleur Livres 2005
http://www.educationsante.be/es/article.php?id=672

HSL16347
Peneff J
La France malade de ses médecins Paris: Les empêcheurs de penser en rond 2005
http://doctorants.mshparisnord.org/actualite/article.php3?id_article=26

HSL16350
Urfalino P
Le grand méchant loup pharmaceutique. Angoisse ou vigilance? Paris: Textuel 2005
http://www.amazon.fr/grand-méchant-loup-pharmaceutique-vigilance/dp/2845971621

HSL17364
Rothman KJ, Greenland S.
Causation and causal inference in epidemiology.
Am J Public Health 2005; 95:
http://ajph.aphapublications.org/cgi/content/full/95/S1/S144?view=long&pmid=16030331

HSL19041
Schwartz LM, Woloshin S, Birkmeyer JD
How do elderly patients decide where to go for major surgery? Telephone interview survey.
BMJ 2005 8; 20:(11):996-1000
http://www.bmj.com/content/331/7520/821.long

HSL19385
Chintagunta PK, Desiraju R
Strategic Pricing and Detailing Behavior in International Markets
Marketing Science 2005; 24:(1):67-80
http://mktsci.journal.informs.org/cgi/content/abstract/24/1/67

HSL20030
Costa C, Papacosta C
Doctors versus Drug Reps: The Corruption of Medical Science
New Doctor 2005; 82:24-25
http://search.informit.com.au/documentSummary;dn=927871162682224;res=IELFSC

HSL19757
Moynihan R, Cassels A
Selling Sicknes
arena magazine 2005 Dec

HSL16351
Van Duppen D
La guerre des médicaments. Pourquoi sont-ils si chers? Bruxelles: Aden 2005
http://www.chapitre.com/CHAPITRE/fr/BOOK/van-duppen-dirk/la-guerre-des-medicaments-pourquoi-sont-ils-si-chers,1639372.aspx

HSL16644
Drury J, Cocking C, Beale J, Hanson C, Rapley F
The phenomenology of empowerment in collective action
Br J Soc Psychol 2005; 44:(3):309-28
http://eprints.sussex.ac.uk/2063/

HSL19875
Cassels A
Donuts for doctors: Buying the medical profession
Common Ground 2005 Sep
http://www.commonground.ca/iss/0509170/cg170_donuts.shtml

HSL20032
Haynes S
Pharma relationship healthy
Medical Observer 2005 Jan15

HSL20148
Hollon MF.
Direct-to-consumer advertising: a haphazard approach to health promotion.
JAMA 2005 27; 293:(16):2030-3
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.293.16.2030

HSL20280
O'Toole TP, Kathuria N, Mishra M, Schukart D.
Teaching professionalism within a community context: perspectives from a national demonstration project.
Acad Med 2005 Apr; 80:(4):339-43
http://www.ncbi.nlm.nih.gov/pubmed/15793016

HSL20396
Slawson DC, Shaughnessy AF.
Teaching evidence-based medicine: should we be teaching information management instead?
Acad Med 2005; 80:(7):685-9
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=Q28c5HzQYxKHkZx38Q9rV0XlTy5zLmtnt1lGwXtq1yVNGrNpmmhz!755119086!181195629!8091!-1?issn=1040-2446&volume=80&issue=7&spage=685

HSL20415
Woolf SH, Johnson RE.
The break-even point: when medical advances are less important than improving the fidelity with which they are delivered.
Ann Fam Med 2005; 3:(6):545-52
http://www.annfammed.org/content/3/6/545.long

Page 13 of 13 pages ‹ First  < 11 12 13

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.